301666-87-5

Basic information

• Product Name: 3-Methylpyridine-4-carboxylic acid ethyl ester N-oxide
• Synonyms: 3-Methylpyridine-4-carboxylic acid ethyl ester N-oxide
• CAS NO: 301666-87-5
• Molecular Formula: C₉H₁₁NO₃
• Molecular Weight: 181.18854
• Mol File: 301666-87-5.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-Methylpyridine-4-carboxylic acid ethyl ester N-oxide(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Methylpyridine-4-carboxylic acid ethyl ester N-oxide(301666-87-5)
• EPA Substance Registry System: 3-Methylpyridine-4-carboxylic acid ethyl ester N-oxide(301666-87-5)

Safety Data

• Hazardous Substances Data: 301666-87-5(Hazardous Substances Data)

Upstream product

• 58997-11-8 3-methylisonicotinic acid ethyl ester 

Downstream Products

• 301666-92-2 2-chloro-3-methyl-4-pyridine carboxylic acid ethyl-ester 
• 329794-45-8 (2-chloro-3-methylpyridin-4-yl)methanol 
• 479612-36-7 (2-chloro-5-methylpyridin-4-yl)methanol 

Relevant articles and documents

Potent N-(1,3-Thiazol-2-yl)pyridin-2-amine vascular endothelial growth factor receptor tyrosine kinase inhibitors with excellent pharmacokinetics and low affinity for the hERG ion channel

A series of N-(1,3-thiazol-2-yl)pyridin-2-amine KDR kinase inhibitors have been developed that possess optimal properties. Compounds have been discovered that exhibit excellent in vivo potency. The particular challenges of overcoming hERG binding activity and QTc increases in vivo in addition to achieving good pharmacokinetics have been acomplished by discovering a unique class of amine substituents. These compounds have a favorable kinase selectivity profile that can be accentuated with appropriate substitution.

NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND BENAMIDE COMPOUNDS AND DRUGS CONTAINING THE SAME

Disclosed are compounds represented by formula (I) which have triglyceride biosynthesis inhibitory activity in the liver and inhibitory activity against the secretion of apolipoprotein B-containing lipoprotein from the liver and particularly have excellent inhibitory activity against the secretion of apolipoprotein B-containing lipoprotein, are free from side effect of accumulation of lipids in the liver, and are useful for the treatment and prevention of hyperlipidemia and arteriosclerotic diseases. In formula (I), R1 and R2 represent alkyl, alkoxy, cycloalkyl, phenyl, alkenyl, alkynyl, or a five- or six-membered saturated or unsaturated heterocyclic ring, or R1 and R2, together with a nitrogen atom to which R1 and R2 are attached, may form a ring; R3 and R4 represent a hydrogen atom, alkyl, a halogen atom, hydroxyl, nitrile, alkoxycarbonyl, alkoxy, or carboxyl; or R2 and R3 may be attached to each other to form -(CH2)m-, -N=CH-, -CH=N-, or -(C1-6 alkyl)C=N-; A, D, E, and G each represent a carbon atom, or any one of A, D, E, and G represents a nitrogen atom with the other three each representing a carbon atom; Q represents a nitrogen atom or a carbon atom; Y represents a group represented by formula (II) wherein X represents a hydrogen atom, group -C(=O)N(R5)R6 or group -C(=O)OR7, R8 is absent or represents a bond, an oxygen atom, a sulfur atom, -SO2-, -SO-, -CH2-CH2-, or - CH=CH-, and R9 and R10 represent a hydrogen atom, alkyl, alkoxy, a halogen atom, or hydroxyl; and Z represents - (CH2)n-, -O-(CH2)i-, or -C(=O)NH-(CH2)i-.